Epilepsy is a common, serious neurological disorder worldwide. Although this disease can
be successfully treated in most cases, not all patients respond favorably to medical …

Major developments in technologies and methodologies, evolving confidence in high-
throughput and genome-wide approaches, and a continuing research effort into the genetics …

The mechanisms underlying the development of drug resistance in epilepsy are complex
and, at this time, not fully understood. It is widely accepted that the efficacy of an antiepileptic …

Drug resistance in epilepsy affects about a third of patients and is an important clinical
problem, associated with increased morbidity and mortality. It is important to consider …

Objective: Resistance to anti-seizure medications (ASMs) presents a significant hurdle in the
treatment of people with epilepsy. Genetic markers for resistance to individual ASMs could …

Epilepsy drug-resistance may depend on the metabolism of antiepileptic drugs (AEDs),
transport to the epileptic focus and/or target sensitivity. Furthermore, drug response depends …

Pharmacoresistance to antiepileptic drugs (AED s) is a barrier to seizure freedom for many
persons with epilepsy. For nearly two decades, pharmacoresistance has been framed in …

Introduction: Although novel antiepileptic drugs (AEDs) have been recently released, the
issue of drug resistance in epileptic patients remains unsolved and largely unpredictable …

Pharmacogenomic studies in epilepsy are justified by the high prevalence rate of this
disease and the high cost of its treatment, frequent drug resistance, different response to the …

Introduction The present evidence indicates that approximately 70% of patients with
epilepsy can be successfully treated with antiepileptic drugs (AEDs). A significant proportion …